Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20174478 | 0.98 | ALOX5 (0.34) | ALOX5SLC9A1ADORA2AADORA1L3MBTL1 | |
| SCHEMBL20174499 | 0.91 | S1PR5 (0.36) | ALOX5SLC9A1F9L3MBTL1 | |
| SCHEMBL22326564 | 0.89 | MEN1 (0.36) | ALOX5SLC9A1ADORA2AADORA1F9 | |
| SCHEMBL20174456 | 0.89 | MEN1 (0.36) | ALOX5SLC9A1ADORA2AADORA1F9 | |
| SCHEMBL20179291 | 0.89 | MEN1 (0.34) | — | |
| SCHEMBL20174460 | 0.88 | L3MBTL1 (0.35) | SLC9A1ADORA2AADORA1F9ADORA3 | |
| SCHEMBL20174485 | 0.88 | MEN1 (0.36) | ALOX5SLC9A1ADORA2AADORA1F9 | |
| SCHEMBL20174525 | 0.88 | MEN1 (0.36) | SLC9A1 | |
| SCHEMBL20174445 | 0.86 | MEN1 (0.34) | ALOX5SLC9A1ADORA2AADORA1F9 | |
| SCHEMBL22326533 | 0.86 | MEN1 (0.34) | ALOX5SLC9A1ADORA2AADORA1F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-11 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | ALOX5 2705/4885SLC9A1 3444/4885ADORA2A 3056/4885 |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | ALOX5 2705/4885SLC9A1 3444/4885ADORA2A 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.